Resources

NEW YORK, May 06, 2020 – FRONTEO (TSE: 2158) FRONTEO has announced the identification of 450 candidate compounds in its research on the novel coronavirus through their proprietary AI system “Cascade Eye”.

Using the previously announced (April 24, 2020) pathway map, also created through the drug discovery support...

NEW YORK, April 30, 2020 – FRONTEO (TSE: 2158) FRONTEO has announced the successful creation of a pathway map for the novel coronavirus infection (COVID-19), using its proprietary AI system “Cascade Eye”.

The pathway map visually identifies crucial molecules, genes, and drug candidates in relation to COVID-19.

...

NEW YORK, April 30, 2020 – FRONTEO (TSE: 2158) FRONTEO has announced the successful creation of a pathway map for the novel coronavirus infection (COVID-19), using its proprietary AI system “Cascade Eye”.

The pathway map visually identifies crucial molecules, genes, and drug candidates in relation to COVID-19.

...

NEW YORK, April 15, 2020 – FRONTEO (TSE: 2158) Kyowa Pharmaceutical and FRONTEO have partnered to develop an AI-based dementia diagnosis support system, using FRONTEO’s proprietary natural language processing AI Concept Encoder.

The Dementia Diagnosis Support System (DDSS), powered by FRONTEO’s AI Concept Encoder...

NEW YORK, April 15, 2020 – FRONTEO (TSE: 2158) Kyowa Pharmaceutical and FRONTEO have partnered to develop an AI-based dementia diagnosis support system, using FRONTEO’s proprietary natural language processing AI Concept Encoder.

The Dementia Diagnosis Support System (DDSS), powered by FRONTEO’s AI Concept Encoder...

VDI solution by Google Cloud and FRONTEO’s AI Review “KIBIT Automator” will allow secure review platform access without compromising performance for attorneys working remotely.

NEW YORK, March 25, 2020 – FRONTEO (TSE: 2158), a leading eDiscovery services provider, has migrated its Managed Review Service serviced...